Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy

At five years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (PDR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news